Shanghai Haohai Biological Technology Co., Ltd.

SEHK:6826 Stock Report

Market Cap: HK$11.2b

Shanghai Haohai Biological Technology Future Growth

Future criteria checks 4/6

Shanghai Haohai Biological Technology is forecast to grow earnings and revenue by 21.8% and 14.8% per annum respectively. EPS is expected to grow by 23.2% per annum. Return on equity is forecast to be 9.8% in 3 years.

Key information

21.8%

Earnings growth rate

23.17%

EPS growth rate

Biotechs earnings growth39.6%
Revenue growth rate14.8%
Future return on equity9.79%
Analyst coverage

Low

Last updated01 Dec 2025

Recent future growth updates

Recent updates

These Analysts Just Made A Substantial Downgrade To Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) EPS Forecasts

Dec 02
These Analysts Just Made A Substantial Downgrade To Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) EPS Forecasts

Shanghai Haohai Biological Technology's (HKG:6826) Problems Go Beyond Weak Profit

Oct 31
Shanghai Haohai Biological Technology's (HKG:6826) Problems Go Beyond Weak Profit

Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) P/E Is On The Mark

Jul 17
Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) P/E Is On The Mark

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Safely

Mar 19
These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Safely

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease

Jul 25
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease

Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All

May 22
Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Apr 17
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?

Feb 12
Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Nov 14
Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Jul 28
Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

Mar 09
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Nov 25
These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Jul 30
Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price

May 08
Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Apr 19
Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Mar 04
Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Mar 03
Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?

Jan 10
Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Oct 08
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly

Jul 07
Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly

Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%

May 27
Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%

Earnings and Revenue Growth Forecasts

SEHK:6826 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20273,482649N/A7472
12/31/20262,879563N/AN/A1
12/31/20252,637466N/AN/A1
9/30/20252,504384374595N/A
6/30/20252,580396393623N/A
3/31/20252,652413387658N/A
12/31/20242,680420283649N/A
9/30/20242,728430325674N/A
6/30/20242,726446296679N/A
3/31/20242,670432239630N/A
12/31/20232,635416367634N/A
9/30/20232,50334699442N/A
6/30/20232,46031592401N/A
3/31/20232,237226-35254N/A
12/31/20222,103180-86231N/A
9/30/20222,06320352343N/A
6/30/20221,86119257336N/A
3/31/20221,80527264339N/A
12/31/20211,75035270342N/A
9/30/20211,702428115333N/A
6/30/20211,674434120342N/A
3/31/20211,594370N/AN/AN/A
12/31/20201,32423066262N/A
9/30/20201,343232-20258N/A
6/30/20201,3062166258N/A
3/31/20201,437279N/AN/AN/A
12/31/20191,595371-50349N/A
9/30/20191,537353-8286N/A
6/30/20191,570386N/A302N/A
3/31/20191,478375N/AN/AN/A
12/31/20181,546415N/A391N/A
9/30/20181,523411N/A398N/A
6/30/20181,501408N/A404N/A
3/31/20181,423390N/A374N/A
12/31/20171,345372N/A343N/A
9/30/20171,214351N/A330N/A
6/30/20171,083329N/A317N/A
3/31/2017967317N/A286N/A
12/31/2016851305N/A254N/A
9/30/2016787295N/A245N/A
6/30/2016724284N/A235N/A
3/31/2016694279N/A252N/A
12/31/2015664273N/A269N/A
9/30/2015630258N/A244N/A
6/30/2015597243N/A219N/A
3/31/2015556213N/A181N/A
12/31/2014516184N/A142N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6826's forecast earnings growth (21.8% per year) is above the savings rate (2.8%).

Earnings vs Market: 6826's earnings (21.8% per year) are forecast to grow faster than the Hong Kong market (12.1% per year).

High Growth Earnings: 6826's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 6826's revenue (14.8% per year) is forecast to grow faster than the Hong Kong market (8.5% per year).

High Growth Revenue: 6826's revenue (14.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 6826's Return on Equity is forecast to be low in 3 years time (9.8%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/06 12:01
End of Day Share Price 2025/12/05 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shanghai Haohai Biological Technology Co., Ltd. is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xiaofang XuCitic Securities Co., Ltd.
Jia'nan ZhaoCitigroup Inc
null nullCMB International Securities Limited